HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide
[...] Read more »Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
- Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1–34) tablet treatment, EB613 on trabecular and cortical bone, and [...] Read more »
Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach
- Funding supports next–generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug–repurposing
- Read more »
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
- FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density [...] Read more »
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A [...] Read more »
Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global Immunization at Sabin
WASHINGTON, July 21, 2025 (GLOBE NEWSWIRE) — Renowned global health expert Rebecca Martin, PhD, recognized internationally for her leadership in developing and implementing immunization programs and [...] Read more »
علم Superhumans الجديد: نظام الذكاء الاصطناعي BioSport™ يكشف النقاب عن الإمكانات الرياضية الخفية
كالجاري، ألبرتا ونيويورك, July 16, 2025 (GLOBE NEWSWIRE) —
Read more »
The New Science of Superhumans: The BioSport™ AI System Unlocks Hidden Athlete Potential
CALGARY, Alberta and NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — In a move that signals a new era in athlete safety and performance science, The BioSport™ Health Inc, a precision health technology company, today unveiled its [...] Read more »
الإمارات العربية المتحدة تعتمد المكمل Longevity+ من BioAro، فاتحة المجال إلى إمكانات تسويقية كبيرة في مجال الصحة الوقائية العالمية
كالجاري، ألبرتا, July 08, 2025 (GLOBE NEWSWIRE) — في خطوة مهمة [...] Read more »
UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) — In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch [...] Read more »
Les Émirats arabes unis approuvent le complément Longevity+ de BioAro, ouvrant la voie à un fort potentiel sur le marché mondial de la santé préventive
CALGARY, Alberta, 08 juill. 2025 (GLOBE NEWSWIRE) — Dans une avancée majeure à l’intersection de la biotechnologie, de la santé préventive et des tendances commerciales en matière [...] Read more »
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in [...] Read more »
Fortrea & Emery Pharma Anunciam Colaboração Estratégica para Fornecer Estudos de Interação Medicamentosa Usando Rifampicina em Conformidade com o FDA
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — A Read more »